KR101719084B1 - 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들 - Google Patents

새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들 Download PDF

Info

Publication number
KR101719084B1
KR101719084B1 KR1020157015922A KR20157015922A KR101719084B1 KR 101719084 B1 KR101719084 B1 KR 101719084B1 KR 1020157015922 A KR1020157015922 A KR 1020157015922A KR 20157015922 A KR20157015922 A KR 20157015922A KR 101719084 B1 KR101719084 B1 KR 101719084B1
Authority
KR
South Korea
Prior art keywords
antibody
met
antibodies
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157015922A
Other languages
English (en)
Korean (ko)
Other versions
KR20150070451A (ko
Inventor
릴리앙 고에뜨쉬
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101719084(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20150070451A publication Critical patent/KR20150070451A/ko
Application granted granted Critical
Publication of KR101719084B1 publication Critical patent/KR101719084B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
KR1020157015922A 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들 Active KR101719084B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
US60/929,789 2007-07-12
EP07301231.2 2007-07-12
EP07301231A EP2014681A1 (en) 2007-07-12 2007-07-12 Novel antibodies inhibiting c-met dimerization, and uses thereof
US2063908P 2008-01-11 2008-01-11
US61/020,639 2008-01-11
PCT/EP2008/059026 WO2009007427A2 (en) 2007-07-12 2008-07-10 Novel antibodies inhibiting c-met dimerization, and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107003216A Division KR101625234B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020167002898A Division KR101701685B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
KR1020167002899A Division KR101701686B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들

Publications (2)

Publication Number Publication Date
KR20150070451A KR20150070451A (ko) 2015-06-24
KR101719084B1 true KR101719084B1 (ko) 2017-03-22

Family

ID=38871713

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157015922A Active KR101719084B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
KR1020167002899A Active KR101701686B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
KR1020167002898A Active KR101701685B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
KR1020107003216A Active KR101625234B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020167002899A Active KR101701686B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
KR1020167002898A Active KR101701685B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
KR1020107003216A Active KR101625234B1 (ko) 2007-07-12 2008-07-10 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들

Country Status (35)

Country Link
US (6) US8329173B2 (enExample)
EP (6) EP2014681A1 (enExample)
JP (4) JP5562844B2 (enExample)
KR (4) KR101719084B1 (enExample)
CN (4) CN101981054B (enExample)
AR (4) AR067517A1 (enExample)
AU (1) AU2008274171B2 (enExample)
BR (1) BRPI0815564B8 (enExample)
CA (4) CA2982484C (enExample)
CL (1) CL2008002015A1 (enExample)
CO (1) CO6170364A2 (enExample)
CY (1) CY1116608T1 (enExample)
DK (1) DK2188312T3 (enExample)
ES (5) ES2693542T3 (enExample)
HR (1) HRP20150887T1 (enExample)
HU (1) HUE026026T2 (enExample)
IL (5) IL203114A (enExample)
MA (1) MA31977B1 (enExample)
ME (1) ME02341B (enExample)
MX (3) MX345391B (enExample)
MY (1) MY158756A (enExample)
NZ (4) NZ583041A (enExample)
PA (1) PA8789201A1 (enExample)
PH (3) PH12018502039A1 (enExample)
PL (1) PL2188312T3 (enExample)
PT (1) PT2188312E (enExample)
RS (1) RS54197B1 (enExample)
RU (1) RU2552161C2 (enExample)
SA (1) SA08290423B1 (enExample)
SG (1) SG183015A1 (enExample)
SI (1) SI2188312T1 (enExample)
TN (1) TN2010000016A1 (enExample)
TW (4) TWI602830B (enExample)
WO (1) WO2009007427A2 (enExample)
ZA (1) ZA201000966B (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US9469691B2 (en) * 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
EP3511342B1 (en) * 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
AU2011296085A1 (en) * 2010-09-03 2013-03-28 Academia Sinica Anti-c-Met antibody and methods of use thereof
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2635603B1 (en) * 2010-11-03 2016-03-23 Argen-X Nv C-met antibody combinations
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
EP4218933A1 (en) * 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
FI2974737T3 (fi) 2011-06-23 2026-01-22 Ablynx Nv Tekniikoita tietyn proteiinihäiriön ennakoimiseksi, havaitsemiseksi ja vähentämiseksi immunoglobuliinin yhtä muuttuvaa domeenia käsittävissä määrityksissä
CN107090038A (zh) * 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
EP2747783B1 (en) * 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
KR20140095096A (ko) 2011-11-21 2014-07-31 제넨테크, 인크. 항-c-met 항체의 정제
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
US9376485B2 (en) 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2863946A4 (en) 2012-06-21 2016-04-13 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
CN105705519A (zh) 2013-03-06 2016-06-22 梅里麦克制药股份有限公司 抗C-MET串联Fc双特异性抗体
NZ712035A (en) 2013-03-13 2019-06-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CA2944717A1 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
EP3200825A4 (en) 2014-10-03 2018-03-21 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
WO2016079194A1 (en) * 2014-11-20 2016-05-26 Stichting Katholieke Universiteit A novel auto-active and intracellular mutant of met
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
US11426468B2 (en) 2014-12-19 2022-08-30 Ablynx N.V. Cysteine linked nanobody dimers
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
US10273305B2 (en) 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US20190194345A1 (en) * 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
MX2018014175A (es) 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
WO2018009499A1 (en) * 2016-07-06 2018-01-11 Celgene Corporation Antibodies with low immunogenicity and uses thereof
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2019018538A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. RECOMBINANT ANTIBODIES BINDING TO CD123
WO2019117691A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
RS66546B1 (sr) * 2018-03-24 2025-03-31 Regeneron Pharma Genetički modifikovani miševi ili pacovi za dobijanje terapeutskih antitela protiv peptid‑mhc kompleksa, postupci za njihovo dobijanje i upotrebe
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
MX2022014013A (es) 2020-05-08 2023-01-30 Academia Sinica Vacunas quimericas contra la influenza.
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
US20240117061A1 (en) * 2020-12-16 2024-04-11 Wuhan Yzy Biopharma Co., Ltd. Anti-bcma antibody, preparation method therefor and application thereof
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
CA3214989A1 (en) 2021-04-06 2022-10-13 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
IL318755A (en) 2021-04-12 2025-04-01 Academia Sinica Improved vaccine for the coronavirus
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
AU2024255035B2 (en) 2023-04-08 2025-08-07 Rock Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
WO2024215614A2 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
EP0970126B1 (en) * 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2476776A1 (en) * 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ATE465181T1 (de) * 2004-08-05 2010-05-15 Genentech Inc Humanisierte anti-cmet-antagonisten
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
MX2007009466A (es) * 2005-02-10 2007-12-07 Baylor Res Inst Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
EA021669B1 (ru) 2005-07-18 2015-08-31 Амджен Инк. Нейтрализующие антитела человека против b7rp1
EP2311876A3 (en) 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
EP2192188A1 (en) 2006-02-06 2010-06-02 Metheresis Translational Research SA Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation

Also Published As

Publication number Publication date
KR20160019974A (ko) 2016-02-22
KR20150070451A (ko) 2015-06-24
EP2535357B1 (en) 2018-08-08
CA2982484C (en) 2021-06-01
IL223106B (en) 2020-06-30
EP2415785A1 (en) 2012-02-08
IL223105A0 (en) 2012-12-31
CA2694418C (en) 2018-03-27
EP2188312B1 (en) 2015-05-27
PA8789201A1 (es) 2009-08-26
CN101981054B (zh) 2015-04-15
SG183015A1 (en) 2012-08-30
TW201605892A (zh) 2016-02-16
CA2982484A1 (en) 2009-01-15
US20150252114A1 (en) 2015-09-10
MX341012B (es) 2016-08-03
RU2552161C2 (ru) 2015-06-10
HUE026026T2 (en) 2016-05-30
EP2188312A2 (en) 2010-05-26
TW200911828A (en) 2009-03-16
US20130273060A1 (en) 2013-10-17
CN103183739A (zh) 2013-07-03
JP2010532982A (ja) 2010-10-21
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
AR109535A2 (es) 2018-12-19
SA08290423B1 (ar) 2013-12-23
PH12018502039A1 (en) 2019-08-19
NZ599958A (en) 2013-11-29
DK2188312T3 (en) 2015-08-03
MY158756A (en) 2016-11-15
CA2981821C (en) 2020-07-28
ME02341B (me) 2015-12-31
PT2188312E (pt) 2015-10-05
AU2008274171A1 (en) 2009-01-15
TWI592427B (zh) 2017-07-21
TN2010000016A1 (en) 2011-09-26
TWI602830B (zh) 2017-10-21
KR101701685B1 (ko) 2017-02-01
HK1193619A1 (zh) 2014-09-26
CN103509112A (zh) 2014-01-15
HK1193620A1 (zh) 2014-09-26
EP2535356A1 (en) 2012-12-19
US20130272957A1 (en) 2013-10-17
KR101625234B1 (ko) 2016-05-30
IL223106A0 (en) 2012-12-31
ES2678495T3 (es) 2018-08-13
EP2415784A1 (en) 2012-02-08
TWI549965B (zh) 2016-09-21
PL2188312T3 (pl) 2016-01-29
CO6170364A2 (es) 2010-06-18
JP5562844B2 (ja) 2014-07-30
AU2008274171B2 (en) 2014-02-27
CN103183739B (zh) 2016-08-17
CA2888691A1 (en) 2009-01-15
AR067517A1 (es) 2009-10-14
EP2535357A1 (en) 2012-12-19
BRPI0815564B8 (pt) 2021-05-25
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
HRP20150887T1 (hr) 2015-09-25
HK1149024A1 (en) 2011-09-23
JP2014113155A (ja) 2014-06-26
TW201605891A (zh) 2016-02-16
JP5889923B2 (ja) 2016-03-22
NZ583041A (en) 2012-06-29
MX345391B (es) 2017-01-27
CN103509113B (zh) 2015-10-21
US20100115639A1 (en) 2010-05-06
US8871910B2 (en) 2014-10-28
SI2188312T1 (sl) 2015-09-30
CY1116608T1 (el) 2017-03-15
US8329173B2 (en) 2012-12-11
MX353449B (es) 2018-01-08
KR101701686B1 (ko) 2017-02-01
RU2010104633A (ru) 2011-08-20
IL223109A0 (en) 2012-12-31
EP2014681A1 (en) 2009-01-14
IL223105B (en) 2020-02-27
CN103509112B (zh) 2015-10-21
CN101981054A (zh) 2011-02-23
JP2014113154A (ja) 2014-06-26
EP2415785B1 (en) 2018-04-25
WO2009007427A2 (en) 2009-01-15
BRPI0815564B1 (pt) 2020-01-21
RS54197B1 (sr) 2015-12-31
ZA201000966B (en) 2011-02-23
IL223108B (en) 2019-06-30
BRPI0815564A2 (pt) 2015-02-18
US8889832B2 (en) 2014-11-18
NZ613716A (en) 2015-01-30
JP2014113153A (ja) 2014-06-26
AR109660A2 (es) 2019-01-09
US9107907B2 (en) 2015-08-18
TWI602829B (zh) 2017-10-21
ES2693542T3 (es) 2018-12-12
EP2535356B1 (en) 2018-06-13
EP2415784B1 (en) 2018-06-13
JP5889925B2 (ja) 2016-03-22
CL2008002015A1 (es) 2008-11-21
CN103509113A (zh) 2014-01-15
CA2888691C (en) 2023-01-03
US20140010818A1 (en) 2014-01-09
IL223108A0 (en) 2012-12-31
JP5889924B2 (ja) 2016-03-22
US8871909B2 (en) 2014-10-28
WO2009007427A3 (en) 2009-04-09
AR109659A2 (es) 2019-01-09
IL223109B (en) 2019-06-30
KR20100044212A (ko) 2010-04-29
CA2981821A1 (en) 2009-01-15
US20130280257A1 (en) 2013-10-24
IL203114A (en) 2015-03-31
TW201437231A (zh) 2014-10-01
MA31977B1 (fr) 2011-01-03
CA2694418A1 (en) 2009-01-15
ES2686693T3 (es) 2018-10-19
PH12018502038A1 (en) 2019-08-19
PH12018502040A1 (en) 2019-08-19

Similar Documents

Publication Publication Date Title
KR101719084B1 (ko) 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들
AU2016228280B2 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2014200630B2 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20200225

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000